Working… Menu

Bucillamine in Treatment of Patients With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04504734
Recruitment Status : Enrolling by invitation
First Posted : August 7, 2020
Last Update Posted : November 2, 2021
Information provided by (Responsible Party):
Revive Therapeutics, Ltd.

No Study Results Posted on for this Study
Recruitment Status : Enrolling by invitation
Estimated Primary Completion Date : October 31, 2021
Estimated Study Completion Date : November 30, 2021